Ambulatory Care Self-Assessment Program (ACSAP) Book 1: Cardiology Care (Cert # L239200)
ACPE Numbers: Various – see listing below
Pre-Sale Date: 02/15/2023
Release Date: 03/15/2023
Expiration Dates: 09/15/2023
Activity Type: Application-based
CE Credits: 17.50 contact hours (BPS and ACPE)
Activity Fee: $80 (ASHP member); $120 (non-member)
Activity Overview
This course is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by Board of Pharmacy Specialties (BPS). The course consists of 4 learning modules (see table below) and provides up to 17.50 contact hours of continuing pharmacy education and/or recertification credit.
Learners will be required to review the content and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this course, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice.
These activities are part of the ACCP and ASHP professional development program for BCACP recertification approved by the BPS.
Accreditation
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education.
Target Audience
The target audience for Ambulatory Care Self-Assessment Program (ACSAP) Book 1: Cardiology Careis board-certified and advanced level ambulatory care clinical pharmacists.
Recertification Credit
Board certified pharmacists are eligible to receive up to 16 contact hours of recertification credit for completing this course. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.
|
Learning Activity |
ACPE Number |
Contact Hours |
Assessment Pass Point |
|
Cardiology Care I |
0217-9999-23-022-H01-P |
4.0 ACPE/BPS |
73% |
|
Cardiology Care II |
0217-9999-23-023-H01-P |
4.5 ACPE/BPS |
76% |
|
Cardiology Care III |
0217-9999-23-024-H01-P |
4.5 ACPE/BPS |
73% |
|
Cardiology Care IV |
0217-9999-23-025-H01-P |
4.5 ACPE/BPS |
77% |
Learning Objectives
Cardiology Care I
ACPE #: 0217-9999-23-022-H01-P
Chapter: Updates in the Management of Heart Failure
- Evaluate key recommendations and recent updates in the national guidelines in the treatment of heart failure (HF).
- Analyze drug therapies according to the revised terminology and categories of HF.
- Design practical strategies to optimize individualizedguideline-directed medical therapies.
Chapter: Dyslipidemia Management Updates
- Assess low-density lipoprotein (LDL)-based treatment recommendations and targets based on common clinical dilemmas.
- Evaluate the role and place in therapy of bempedoic acid, inclisiran, and evinacumab in the treatment of dyslipidemia.
- Apply appropriate management strategies for lowering LDL in statin-intolerant patients.
Cardiology Care II
ACPE #: 0217-9999-23-023-H01-P
Chapter: DOAC Use in Special Populations
- Account for the classification of special populations for direct oral anticoagulant (DOAC) use.
- Analyze the emerging evidence for DOAC use in specific special populations.
- Apply evidence and societal guidelines to guide the use of DOACs in specific patient populations.
- Evaluate the degree of uncertainty of DOAC use in specific patient populations.
Chapter: Updates in Cardio-Oncology
- Given a patient on anticancer therapy, evaluate the patient’s risk of developing vascular toxicities, establish treatment goals, and construct a therapeutic plan.
- Devise a risk mitigation and treatment strategy for patients on anticancer therapy at risk of developing heart failure.
- Evaluate which patients on anticancer therapy are at risk of developing atrial fibrillation and design a plan for risk management and monitoring.
- For patients on anticancer therapy, assess individual risk of developing QTc prolongation and develop a plan for prevention, treatment, and surveillance.
- Assess a patient’s risk of developing myocarditis and construct a monitoring and treatment plan.
Cardiology Care III
ACPE #: 0217-9999-23-024-H01-P
Chapter: Stable Ischemic Heart Disease Management Updates
- Distinguish between drug therapy recommendations for cardiovascular (CV) risk reduction and symptomatic relief of symptoms in patients with stable ischemic heart disease (SIHD) based on current guidelines.
- Develop an evidence-based pharmacologic regimen for patients with SIHD for both CV risk reduction and symptomatic relief of symptoms.
- Analyze the optimal use of antithrombotic therapy for patients with SIHD.
- Assess the optimal use of omega-3 fatty acids in patients with SIHD and hypertriglyceridemia.
- Evaluate the impact of colchicine on CV risk reduction in patients with SIHD.
Chapter: Pharmacogenomics and Cardiovascular Disease
- Evaluate the clinical use of pharmacogenomic testing for cardiovascular medications to guide therapeutic recommendations.
- Assess genotype results and other raw pharmacogenomic data to determine actionable prescribing using pharmacogenetic guidelines, resources, and knowledge bases.
- Develop a therapeutic plan for cardiovascular health management incorporating patient-specific clinical factors and pharmacogenomic test results.
- Evaluate the supporting evidence, clinical validity, and clinical use of pharmacogenetic testing for cardiovascular medications with no currently available pharmacogenetic prescribing recommendations.
Cardiology Care IV
ACPE #: 0217-9999-23-025-H01-P
Interactive Case: Role of Colchicine in Secondary Prevention of CVD
- Discover the role of inflammation in the mediation of atherosclerotic disease progression and ultimate events.
- Assess historic strategies targeting inflammation and outcomes related to cardiovascular disease (CVD).
- Analyze the role of colchicine therapy with relation to CVD risk reduction.
- Devise a strategy for integrating colchicine into treatment plans for CV risk reduction.
Interactive Case: Lower Extremity Peripheral Artery Disease
- Justify the need for atherosclerotic risk reduction strategies in a patient with lower extremity peripheral artery disease (LE-PAD).
- Detect whether a patient with LE-PAD has symptoms.
- Evaluate the risk-benefit of antiplatelet therapy for a patient with asymptomatic LE-PAD.
- Design an antithrombotic treatment regimen for a patient with symptomatic LE-PAD.
- Develop an antithrombotic treatment regimen for a patient who underwent revascularization for LE-PAD.
Interactive Case: Telehealth and Self-Monitoring of Blood Pressure
- Evaluate requirements for implementing, conducting, and billing for telehealth services.
- Assess a patient’s home blood pressure monitor and technique.
- Evaluate a patient for primary, resistant, or secondary hypertension.
- Analyze a patient’s home readings, laboratory values, and medical history and recommend appropriate medication.
Faculty
Series Editors
Brian K. Irons, Pharm.D., FCCP, BCACP
Professor
Jerry H. Hodge School of Pharmacy
Texas Tech University Health Sciences Center
Lubbock, Texas
Ashley H. Meredith, Pharm.D., MPH, FCCP, BCACP, BCPS, CDCES
Clinical Professor of Pharmacy Practice
Purdue University
West Lafayette, Indiana
Faculty Panel Chair
Joel C. Marrs, Pharm.D., MPH, BCACP, BCCP, BCPS, CLS
Professor and Coordinator of Clinical Outreach
Department of Clinical Pharmacy and Translational Science
University of Tennessee Health Science Center, College of Pharmacy
Ambulatory Care Clinical Pharmacist Specialist
Department of Pharmacy
Ascension Medical Group—Tennessee
Nashville, Tennessee
Authors
Arthur L. Allen, Pharm.D., CACPAnticoagulation Program Manager
Department of Anticoagulation and Thrombosis Service
VA Salt Lake City Health Care System
Salt Lake City, Utah
Sandra Cuellar, Pharm.D., FHOPA, FASHP, BCOP
Clinical Oncology Pharmacist
Department of Pharmacy Practice UI Health
Clinical Associate Professor
University of Illinois Chicago
College of Pharmacy
Chicago, Illinois
Courtney Doyle-Campbell, Pharm.D., MBA, BCACP, AHSCP-CHC
Clinical Associate Professor of Ambulatory Care
Department of Pharmacy Practice
Western New England University
Springfield, Massachusetts
Clinical Assistant Professor
Department of Pharmacy Practice
University of Illinois Chicago
College of Pharmacy
Chicago, Illinois
Augustus (Rob) Hough, Pharm.D., BCPS, BCCP
Clinical Pharmacy Practitioner – Cardiology
Departments of Pharmacy and Cardiology
West Palm Beach VA Healthcare System
West Palm Beach, Florida
Jeffery L. Kibert II, Pharm.D., BCPS
Clinical Pharmacy Specialist
VA Salt Lake City Health Care System
Salt Lake City, Utah
James C. Lee, Pharm.D., FCCP, BCACP, AACC
Clinical Associate Professor
Department of Pharmacy Practice
University of Illinois at Chicago
College of Pharmacy
Co-Director, Personalized Medicine Program
Department of Ambulatory Pharmacy Services
University of Illinois Hospital & Clinics
Chicago, Illinois
Emily K. McCoy, Pharm.D., FCCP, BCACP
Associate Clinical Professor and Interim Assistant Dean, Mobile Campus
Department of Pharmacy Practice
Auburn University Harrison
College of Pharmacy
Mobile, Alabama
Anticoagulation Clinical Pharmacist Provider
Department of Pharmacy
VA Eastern Colorado Health Care System
Aurora, Colorado
Harleen Singh, Pharm.D., BCPS, BCACP
Clinical Professor
Department of Pharmacy Practice
University of Texas El Paso
El Paso, Texas
Dyson T. Wake, Pharm.D., BCPS
Senior Clinical Specialist – Pharmacogenomics
Mark R. Neaman Center for Personalized Medicine
NorthShore University HealthSystem
Evanston, Illinois
Bruce A. Warden, Pharm.D., FNLA, FASPC, BCPS, CLS
Preventive Cardiology Clinical Pharmacist
Department of Pharmacy, Knight Cardiovascular Institute
Oregon Health & Science University
Portland, Oregon
Kristin Watson, Pharm.D., BCCP
Associate Professor
Department of Pharmacy Practice and Science
University of Maryland
School of Pharmacy
Baltimore, Maryland
Reviewers
Clinical Pharmacist Ambulatory Care
Department of Pharmacy
Cleveland Clinic Hillcrest
Mayfield Heights, Ohio
Clinical Pharmacist, NDPP Program Coordinator, NDPP Lifestyle Coach
Community Care of the Lower Cape Fear
Wilmington, North Carolina
Craig J. Beavers, Pharm.D., FCCP, BCCP, BCPS-AQ Cardiology, CACP
Adjunct Assistant Professor
Department of Pharmacy
Practice University of Kentucky
College of Pharmacy
Lexington, Kentucky
Scott Bolesta, Pharm.D., BCCCP
Associate Professor
Department of Pharmacy Practice
Wilkes University
Wilkes-Barre, Pennsylvania
John Bucheit, Pharm.D., BCACP
Associate Professor
Department of Pharmacotherapy and Outcomes Science
VCU School of Pharmacy
Richmond, Virginia
Amber Cipriani, Pharm.D., BCOP
Precision Medicine Pharmacy Coordinator
Department of Pharmacy
UNC Health Medical Center
Clinical Assistant Professor
Division of Pharmacotherapy and Experimental Therapeutics
UNC Eshelman
School of Pharmacy
Chapel Hill, North Carolina
Associate Professor
Department of Pharmacy Practice
Southwestern Oklahoma State University
Weatherford, Oklahoma
Clinical Pharmacy Specialist
Department of Pharmacy
Oklahoma City Indian Clinic
Oklahoma City, Oklahoma
Nathan P. Clark, Pharm.D., FCCP, BCPS
Clinical Pharmacy Manager
Clinical Pharmacy
Cardiovascular Services
Kaiser Permanente Colorado
Clinical Assistant Professor
University of Colorado
Skaggs School of Pharmacy and Pharmaceutical Sciences
Aurora, Colorado
Clinical Pharmacist Practitioner
Veterans Affairs
Clarksville, Tennessee
Paul P. Dobesh, Pharm.D., FCCP, BCPS, BCCP
Professor
Department of Pharmacy Practice and Science
University of Nebraska Medical Center
College of Pharmacy
Omaha, Nebraska
Clinical Pharmacist and Residency Program Director
Department of Clinical Pharmacy ARcare
Searcy, Arkansas
Clinical Ambulatory Care Pharmacist
Departments of Pharmacy and Family Medicine
Mayo Clinic Health System
Sparta, Wisconsin
Clinical Pharmacist
SFH Anticoagulation Service
Saint Francis Hospital and Medical Center
Trinity Health of New England
Hartford, Connecticut
Chair
Department of Pharmacy and Pharmaceutical Sciences
Lipscomb University
Nashville, Tennessee
Assistant Professor
Department of Pharmacy Practice
Thomas Jefferson College of Pharmacy
Philadelphia, Pennsylvania
Cardiology Pharmacist
Department of Pharmacy
Atrium Health Wake Forest Baptist
Winston-Salem, North Carolina
Assistant Professor of Pharmacy Practice
Department of Pharmacy Practice
South Dakota State University
College of Pharmacy and Allied Health Professions
Brookings, South Dakota
Emily Kosirog, Pharm.D., BCACP
Director of Clinical Pharmacy
Salud Family Health
Ft. Lupton, Colorado
Lindsey A. Krueger, Pharm.D., BCACP
Senior Clinical Pharmacist Specialist
Department of Pharmacotherapy Services
Cambridge Health Alliance
Cambridge, Massachusetts
Clinical Pharmacy Practitioner
Veterans Affairs Clinical Resource Hub
Louisville, Kentucky
Dejan Landup, Pharm.D.
Cardiovascular Clinical Pharmacist
Department of Pharmacy and Chronic Disease Management
Advocate Medical Group
Chicago, Illinois
Suwen Lim, M.S. Pharm., BCOP, BCPS, BCGP, BCACP
Senior Clinical Pharmacist
Department of Oncology Pharmacy
National Cancer Centre
Singapore Republic of Singapore
Edward M. Saito, Pharm.D., BCACP
Associate Professor
School of Pharmacy
Pacific University
Hillsboro, Oregon
Clinical Pharmacist
Virginia Garcia Memorial Health Center
Cornelius, Oregon
Specialty Pharmacy Services Compliance Officer
Department of Specialty Pharmacy Services
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Acknowledgment
The American College of Clinical Pharmacy thanks Sarah L. Anderson, Pharm.D., FCCP, FASHP, BCPS, BCACP, for her contribution to development of the ACSAP 2022-2024 series during her term as Series Editor. Dr. Anderson’s term ended before her employment with Clinical Care Options.
Disclosures
In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.
An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.
Consultancies: Arthur L. Allen (BMS/Pfizer Alliance); Sandra Cuellar (Seagen); Paul P. Dobesh (Pfizer/BMS Alliance; Janssen); Gabriella Douglass (Sanofi); James C. Lee (RxGenomix)
Grants: Gabriella Douglass (Gilead); Bruce A. Warden (Akcea)
Honoraria: Arthur L. Allen (Janssen; Alexion; Astra-Zeneca; Anticoagulation Forum); Sandra Cuellar (Seagen; Genentech)
All other persons in control of content do not have any relevant financial relationships with an ineligible company.
As required by the Standards of Integrity and Independence in Accredited Continuing Education, all relevant financial relationships have been mitigated prior to the CPE activity.
Methods and CE Requirements
Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:
- Complete the attestation statement
- Review all content
- Complete and pass the assessments
- Complete the evaluations
Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.
Development
ACCP and ASHP collaborate on ambulatory care pharmacy activities.